• GEMXX is a mine-to-market enterprise that specializes in the production and distribution of gemstones, like Ammolite, and jewelry on a global scale
• Ammolite is a rare gemstone that exhibits a unique iridescence and is only found in southern Alberta, Canada
• The company recently announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is growing exponentially
• GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand
• Its shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months

Although officially recognized by the Coloured Stones Commission of the World Jewellery Confederation (“CIBJO”) as a semi-precious gemstone in 1981 (https://ibn.fm/bfZNW), Ammolite has a long, rich history. Made from the fossilized shells of now-extinct sea creatures known as Ammonites, Ammolite tells the story of lifeforms that existed more than 71 million years ago. In that period, their remains underwent mineralization and transformation induced by tectonic pressure and glacier water, resulting in the “development of an iridescent, rainbow-like coloring that includes red, yellow, green, and blue, the latter hue being the rarest,” according to an article in The Globe and Mail (https://ibn.fm/ryrBq).

While Ammonite fossils are scattered around the world, Ammolite gemstone is only found on the eastern slopes of the Rocky Mountains – within the Bearpaw geologic formation – in southern Alberta, Canada, making it one of the rarest gems on earth and sought after around the world. The visual allure of Ammolite stems from the fact that it exhibits iridescence and vibrance, which result from the stone’s multiple layers. However, because of these layers, Ammolite is quite fragile and needs to be carefully handled while mining and polishing (https://ibn.fm/B88KL), considerations that guide the meticulous work of the experienced gemstone cutters and jewelry designers at GEMXX (OTC: GEMZ), who have catapulted the company to the upper echelons of finished Ammolite production.

GEMXX is a mine-to-market enterprise specializing in the production and distribution of gemstones and jewelry on a global scale. In the domain of Ammolite mining and processing, the company stands out as the leading producer of top-quality finished Ammolite, surpassing competitors both in terms of production capacity and quality (https://ibn.fm/KbW60). GEMXX relies on a world-class team of gemstone cutters and jewelry designers whose expertise continues to increase the demand for its products.

Just recently, GEMXX announced that demand for its Ammolite in jewelry designs by Kenneth Bradley is exponentially growing. One of the world’s most recognized Ammolite experts, Bradley founded Canadian Ammolite Gems by Kenneth Bradley, an Ammolite jewelry collection. He hosts live, on-air events showcasing uniquely beautiful GEMXX Ammolite gemstones in jewelry by Kenneth Bradley designs and will continue to host multiple Ammolite events annually featuring stunning Ammolite gems curated by GEMXX gemstone cutters (https://ibn.fm/2qms4).

“It is my opinion that GEMXX supplies the finest Ammolite in the world, and that is why I have selected them as the exclusive supplier for my Ammolite jewelry,” commented Bradley.

GEMXX plans to expand gemstone and jewelry production by 300% year over year in response to growing demand, tapping into its proven Ammolite reserves, currently valued at more than $600 million. On its part, the company’s shopping channel division is preparing to supply $5.5 million worth of Ammolite gemstones and jewelry over the next 12 months.

“This is a fundamental step in the company’s expansion plans. GEMXX Ammolite products will now have an expanded on-air presence in the United States, Canada, and Australia,” said Jay Maull, GEMXX’s CEO.

To facilitate this expansion, the company aims to raise $6 million in investment funding through a fully qualified Regulation A (“Reg A”) offering. “This will allow the company to break ground on a new, large-scale Ammolite mine, expand current goldmine operations, and cater to the ever-increasing global demand for its products,” GEMXX says in its investor presentation (https://ibn.fm/bXlQu).

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/ZWx9a) or contact the company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
• This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
• The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
• These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.

As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://ibn.fm/EVk0p). This devotion of a significant proportion of its resources reflects the company’s intent to establish areas of investigation for commercial pursuits while bringing it closer to tapping into vastly untapped markets with the potential for growth in the coming years.

The investments have paid off, with Lexaria having come a step closer to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/zZ96p). So far, previous clinical trials have shown DehydraTECH-processed CBD’s ability to lower blood pressure in patients over multiple weeks, a tremendous achievement for the company and for its technology.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/G9dm6).

This success has been replicated in other studies, most notably diabetes. In Lexaria’s pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels. With the American Diabetes Association (“ADA”) estimating the number of Americans with diabetes at 37.3 million as of 2019, there is a dire need for viable treatment options, and Lexaria is looking to address that (https://ibn.fm/A2R5W).

Lexaria’s DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market. Its NIC-H22-1 human nicotine study demonstrated a statistically significant difference between the time taken to achieve maximum blood saturation levels (“Tmax”) for DehydraTECH-nicotine at 2.3 and 3.1 minutes faster than alternatives currently in the market. In addition, DehydraTECH-nicotine represented a 15% and 20% faster response to achieve maximum blood saturation, a feat that few other players in the market have achieved.

“Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” noted Mr. Bunka.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he added (https://ibn.fm/kxfsA).

Even with its achievements so far, Lexaria remains committed to pushing the envelope regarding the research and development of its DehydraTECH technology. So far, it has demonstrated its incredible potential across various areas of application as well as its viability in the market. The consistent push for further development reflects Lexaria’s understanding of its mission and commitment to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

by Elaine Mendonça

On September 28, 2023, Clene Inc. (NASDAQ: CLNN) made an exciting announcement regarding their groundbreaking research on the investigational drug CNM-Au8. In a scientific paper published in the esteemed journal Small, Clene Inc. revealed the catalytic mechanism of action behind the therapeutic properties of CNM-Au8.

The study showcased the remarkable neuroprotective abilities of CNM-Au8, attributing its success to its unique catalytic activity. When exposed to toxins that typically lead to neuronal death, CNM-Au8 treatment exhibited a remarkable ability to promote cell survival and preserve the intricate network of neurites.

To truly understand the underlying mechanisms responsible for CNM-Au8’s neuroprotective function, extensive studies were conducted. These studies focused on characterizing the catalytic reactions facilitated by CNM-Au8, aiming to unravel how it effectively regulates cellular health and metabolism. The findings were nothing short of groundbreaking, shedding light on the exceptional therapeutic potential of CNM-Au8.

The distinct mechanism of action exhibited by CNM-Au8, coupled with its wide applicability in preserving neuronal health, positions it as a promising new treatment for various neurodegenerative diseases. This research opens up exciting possibilities for addressing multiple assaults on neuronal health and offers hope for patients worldwide.

Clene Inc. (NASDAQ: CLNN) Stock Performance and Financial Indicators: September 28, 2023 Analysis

CLNN stock had a relatively stable performance on September 28, 2023, with a previous close of $0.53 and an open of $0.52. Throughout the day, the stock fluctuated within a range of $0.52 to $0.55. The trading volume was 533,547 shares, which is slightly higher than the average volume of 528,357 shares over the past three months. The market capitalization of CLNN stands at $59.5 million.

Looking at the financial indicators, CLNN has experienced significant challenges in terms of earnings growth. The earnings growth for the previous year was -190.01%, indicating a substantial decline. However, there is no available information on earnings growth for the current year or the next five years. The revenue growth for the last year was also negative, with a decline of 34.58%.

The price-to-earnings (P/E) ratio for CLNN is not provided (NM), suggesting that the company may have negative earnings or no earnings at all. The price/sales ratio is 137.85, indicating that investors are willing to pay a premium for each dollar of sales generated by the company. The price/book ratio is 10.71, which suggests that the stock may be overvalued based on its book value.

Clene Inc. (NASDAQ: CLNN) operates in the health technology sector, specifically in the pharmaceuticals: major industry.

The next reporting date for CLNN is November 7, 2023. Analysts forecast an earnings per share (EPS) of -$0.10 for this quarter. The annual revenue for the previous year was $473,000, while the annual profit was -$29.9 million. The net profit margin for CLNN is a staggering -6,325.16%, indicating significant losses.

Investors should carefully consider these factors before making any investment decisions regarding CLNN stock.

CLNN Stock Shows Impressive Performance with Potential for Significant Growth: Analysts Median Target Estimate

CLNN stock had an impressive performance on September 28, 2023, based on the information provided by CNN Money. The 12-month price forecasts from six analysts for Clene Inc. had a median target of $5.00, with a high estimate of $10.00 and a low estimate of $4.00. This median estimate represents a remarkable increase of 825.93% from the last recorded price of $0.54.

The consensus among the six polled investment analysts is to buy stock in Clene Inc., and this rating has remained steady since September. This indicates a positive sentiment towards the company’s future prospects.

It is important to note that the stock’s current performance is not solely based on the information provided for September 28, 2023. The data source does not provide specific details about the stock’s performance on that particular day. However, the 12-month price forecasts and the consensus among analysts suggest a positive outlook for Clene Inc.

In terms of financials, the current quarter’s earnings per share for Clene Inc. were reported at -$0.10. Additionally, the company’s sales for the same quarter amounted to $117.8K. These figures indicate that Clene Inc. may be experiencing some financial challenges in the short term.

Investors should keep an eye on Clene Inc.’s upcoming reporting date, which is set for November 7. This report may provide more insights into the company’s financial performance and future prospects.

Overall, the information provided suggests that Clene Inc.’s stock has the potential for significant growth, as indicated by the high median target estimate from analysts. However, investors should carefully consider the company’s financial performance and any upcoming reports before making investment decisions.

For more information on Clene visit Clene Inc. (NASDAQ: CLNN)

Third-Party Content

The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/

• As one of the oil and gas leaders, Canada is the third-largest holder of proven oil reserves in the world; the country’s oil and gas sector is not only big but also green, positioning Canada as an energy powerhouse with an eye on a greener future
• The sector reported output growth while slashing emissions, standing as a testament that achieving both growth and environmental sustainability is possible
• Amid Canada’s firm commitment to a greener future, companies like Prospera Energy are set to benefit as the country seizes the opportunity of the burgeoning market while still ensuring sustainability

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a Canadian public oil and gas exploration, exploitation, and development company, remains dedicated to reshaping the future of the oil and gas sector by demonstrating that environmentally responsible production practices can enhance both resource recovery and industry sustainability. After the transformational year in 2022, when the company turned the tide and increased production, revenue, and asset appreciation while lowering liabilities, Prospera appears to be on a hot streak, poised for 2023 record growth. The company has started the execution of Phase 2 in their development plan, which includes increased production in Alberta through medium-oil development and utilization of horizontal well-technology to capture the significant remaining reserves in Saskatchewan.

The growth expectations come amid Canada’s firm commitment to cleaner extraction methods and more efficient practices. A recent report shows that the country’s oil and gas industry has made significant strides in achieving both growth and sustainability, solidifying its position as a global leader in eco-friendly energy production (https://ibn.fm/nPvDu). According to the Canadian Association of Petroleum Producers (“CAPP”), from 2012 to 2021, the sector witnessed a 21% increase in conventional hydrocarbon production while achieving a 24% reduction in carbon dioxide equivalent emissions. Natural gas experienced significant expansion, with production skyrocketing by 35%. Still, it was accompanied by a remarkable decrease in carbon dioxide emissions by 22% and methane emissions by an even more impressive 38%. A recent S&P Global Commodity Insight survey revealed that Canada’s oil sands producers had kept emission levels in 2022 unchanged compared to the year before despite increased output–demonstrating the sector’s potential to outpace emission reduction expectations.

This dedication to simultaneously slashing emissions and expanding production positions Canadian oil and natural gas as reliable and responsible energy sources on a global stage. With an estimated 171.0 billion barrels, Canada is the industry’s powerhouse as the holder of the third-largest proven oil reserve in the world, accounting for 10% of the global oil resources. Proven oil reserves are those that are known to exist and that are expected to be recovered through existing wells with existing equipment and production methods. As technology continues to advance, Canada’s proven oil reserves could grow further as the oil sands alone have potential reserves estimated at more than 300 billion barrels in addition to its substantial untapped tight oil resources (https://ibn.fm/6AxHX). 

As Canada shifts from a traditional oil and gas powerhouse to one of the world’s most ethical and environmentally sustainable oil producers, companies like Prospera are seizing the chance to reshape the industry’s tarnished image due to global warming. The company restructured and optimized operations and has since proven that thriving while prioritizing the environment is achievable in the oil and gas sector.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference
• The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults
• The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11%
• RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas, recently presented at the H.C. Wainwright 25th Annual Global Investment Conference. The conference was held virtually and in person on September 11-13, 2023, at the Lotte New York Palace Hotel in New York City.

The H.C. Wainwright 25th Annual Global Investment Conference is the premier event for companies and investors in life sciences, cryptocurrency, blockchain, fintech, metals, mining, technology, media, telecommunications, cleantech, and more. The three-day event was filled with leading industry keynote speakers, presenting companies, investor one-on-one meetings, networking opportunities, and evening entertainment.

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during this year’s H.C. Wainwright conference. The company’s primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults. UPNEEQ(R) is a once-daily eye drop shown in clinical trials to result in an average lift of one-millimeter to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit.

Patients eligible for treatment with UPNEEQ(R) include adults with droopy or low-lying eyelids, the majority of whom are females. Although the exact prevalence of acquired ptosis is unknown, RVL Pharmaceuticals believes it to be a common age-related condition.

The global medical aesthetics market revenue was estimated at $13.9 billion in 2022. It is expected to grow at a CAGR of 11%, reaching $23.4 billion by 2027. (https://ibn.fm/943Ck). The market’s expansion is believed to be due to factors such as the rising popularity of minimally invasive and non-invasive aesthetic procedures, the rising popularity of aesthetic procedures among older patients, greater accessibility to technologically advanced and user-friendly products, and the rise in demand for aesthetic treatments among the male population.

Access to UPNEEQ(R) is supported by the company’s Elevate eCommerce platform, launched in July 2023. The Elevate platform enables patient subscription ordering across channels, including HCP direct practices, HCP virtual practices, and RVL pharmacy eye care patients. The platform enhances patient retention by allowing for refills to be fulfilled by RVL Pharmacy and delivered directly to the patient’s home. At the same time, HCPs continue to share customer refills’ value. The pharmacy also offers auto-replenishment for HCPs that dispense UPNEEQ(R) through their practice.

By participating in the H.C. Wainwright conference, RVL Pharmaceuticals was able to present the benefits and significance of UPNEEQ(R) to other public companies, industry executives, business development executives, institutional investors, private equity firms, and venture capitalists.

For more information, visit the company’s website at www.RVLPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP

• In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial
• In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises
• As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets
• Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”).

Its lead drug candidate is CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age
• All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product
• Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who participated in the trial survived and remained heart transplant-free for up to 5 years of age after receiving the company’s lead investigational product, Lomecel-B(TM) (https://ibn.fm/TIOTm).

This study explored Lomecel-B(TM)’s potential to address hypoplastic left heart syndrome (“HLHS”), a congenital disability affecting normal blood flow through the heart. Historical results have shown that children with the condition have approximately 20% mortality by five years, with as many as 1,025, or one out of every 3,841 babies in the U.S. born with the condition (https://ibn.fm/gnCG7).

From the ELPIS I trial, all ten patients enrolled were monitored for at least 3.5 years after treatment with Lomecel-B(TM). To date, 5 out of the 5 eligible patients from the trial have already undergone the last of the three surgeries required to treat the condition, with Longeveron expected to present updated data from this process later in 2023.

“We are pleased to share additional long-term follow-up data demonstrating the continued survival of the ELPIS I trial participants,” noted Joshua M. Hare, M.D., Co-Founder, Chief Science Officer, and Chairman of the Board of Directors at Longeveron (https://ibn.fm/y8WmA).

ELPIS I is an open-label, Phase 1b trial specifically designed to evaluate the safety of Lomecel-B(TM) in patients with HLHS. Initial results demonstrated that the study met its primary safety endpoint and that all patients were alive, transplant-free, and maintained their expected growth rate one year after treatment. With these promising results, Longeveron is optimistic about the results to be shared later in the year. In addition, its management is excited for the next steps in the study, particularly as the company continues to enroll patients at the eight sites in the ELPIS II trial, a 38-patient, randomized (1:1) blinded, controlled Phase 2 clinical trial designed to evaluate the safety and efficacy of intramyocardial injection of Lomecel-B(TM) in infants with HLHS undergoing the Glenn Procedure.

“There is a major unmet need among children with HLHS, and today’s data highlighting the 100% survival rate of ELPIS I patients up to 5 years post-treatment underscore the potential opportunity for Lomecel-B(TM) as a much-needed therapeutic innovation for this patient group,” noted Sunjay Kaushal, M.D., Ph.D. Principal Investigator of the ELPIS I trial.

There is no FDA-approved medical treatment for HLHS, leaving a vast untapped market for Longeveron. So far, the product has received Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the United States Food and Drug Administration (“FDA”), which represent significant milestones for the company as it continues its work towards seeking FDA approval of Lomecel-B(TM) for HLHS.

 With these studies, the company looks to tap into several market opportunities, projecting that the potential market size for its Lomecel-B(TM) in treating HLHS could be up to $1 billion annually, globally. In addition, the company is investigating Lomecel-B(TM) to address Alzheimer’s disease, which represents a market between $5 billion to $10 billion annually, as well as Aging-related Frailty, which represents a market between $4 billion and $8 billion globally per year. 

For more information, visit the company’s website at www.Longeveron.com 

Forward-Looking Statements

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the company’s product candidates, and other positive results; the timing and focus of the company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the company’s product candidates; the company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the company’s ability to attract and retain such personnel; the company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the company’s results and forward-looking statements are disclosed in the company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

• D-Wave is the world’s first commercial supplier of quantum computing solutions
• D-Wave’s customers have built quantum and quantum-hybrid applications in areas such as resource scheduling, mobility, logistics, drug discovery, portfolio optimization, manufacturing processes, and more
• Using D-Wave’s annealing quantum computing solutions, SavantX was able to increase deliveries per crane per day by 60% at Pier 300 at the Port of Los Angeles, one of the nation’s largest ports

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, is helping customers solve highly complex business problems today, helping to drive operational efficiencies, reduce costs, and increase revenue. By harnessing the power of its proprietary annealing quantum computing technology, D-Wave is able to address challenging optimization problems across a wide range of use cases, including logistics, drug discovery, resource scheduling, manufacturing processes and financial modeling.

The company’s pursuit of practical quantum computing has resulted in its technology being used by some of today’s most advanced enterprises worldwide, including numerous Forbes Global 2000 companies. In a September 11, 2023 interview with Bloomberg Technology, D-Wave CEO Alan Baratz said that he believes quantum technology “is going to fundamentally transform the way businesses operate and have a huge impact on the social and economic environment,” (https://ibn.fm/GG7zI).

One area where D-Wave’s quantum computing solutions have been applied successfully is logistics optimization at Pier 300 at the Port of Los Angeles, the nation’s largest facility for handling shipborne cargo. In 2021, the equivalent of more than 10 million 20-foot container units were transferred from ships to trucks to take them to their inland destinations. At a time when supply chains face increased disruptions, efficiency is key to ensuring the movement of goods keeps pace. Quantum computing can offer an important approach for identifying solutions to complex logistical problems like those faced by the port.

SavantX used D-Wave’s quantum technology to explore efficiencies at Pier 300, one of the port’s largest terminals, creating an application that demonstrated efficiency gains by optimizing equipment usage and personnel while ensuring that containers were cleared from the port as quickly as possible. SavantX saw a 60% increase in deliveries per crane per day using quantum computing for logistical optimization. (https://ibn.fm/hTOHg).

“Not all problems are optimization problems, but for the ones that are, there’s a huge opportunity to bring value into the equation,” said Ed Heinbockel, CEO of SavantX. “We’ve tasted the power of quantum, and we’re very, very excited about it.”

Demonstrating the capabilities of its quantum and quantum-hybrid solutions in solving real-world problems, D-Wave’s website features numerous customer success stories to show the impact its technology is having today (https://ibn.fm/9ZbAm).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to share cutting-edge innovations, strategies, and growth opportunities.

The highly anticipated 8th Annual Investor Conference provides a unique platform for evolving and established small-cap growth companies within the healthcare, technology, and consumer sectors. It’s a unique opportunity for ground-breaking businesses to showcase their products and services to a wide audience. The conference promises to provide ample networking opportunities to business owners who are eager to revolutionize the industry and deliver an enhanced ROI.

Promoting Investment Excellence

The Dawson James Small Cap Growth Conference will be dignified by a select, invite-only audience, that includes Institutional Funds, Family Offices, and a significant base of High Net Worth Accredited Investors. As an incredible blend of the brightest minds and opportunities, the conference aims to leverage the massive potential that small-cap growth companies offer. This rare gathering of professionals and extraordinary minds will explore a diverse range of investment prospects to set the tone for the day.

The core of the conference lies in the business presentations, where selected small-cap growth companies will take the stage. The conference will start at 7:30 a.m. with registration and a hearty breakfast to fuel participants for the exciting day ahead. Following the breakfast, a panel of eminent professionals will delve into the current investment setting, sharing valuable perspectives and insights into the growth potential and investment opportunities.  

Register today and be a part of small-cap growth and innovation.

Participating Companies as of 09/19/2023

• Aditxt, Inc. (NASDAQ: ADTX) (www.Aditxt.com) 
• Annovis Bio Inc. (NYSE American: ANVS) (www.AnnovisBio.com)
• bioAffinity Technologies, Inc. (NASDAQ: BIAF) (https://bioaffinitytech.com)
• Bitfarms (NASDAQ: BITF) (https://Bitfarms.com/)
• Borqs Technologies, Inc. (NASDAQ: BRQS) (www.Borqs.com)
• Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) (www.CitiusPharma.com)
• Clearmind Medicine Inc. (NASDAQ: CMND) (www.ClearmindMedicine.com)
• Cyclo Therapeutics (NASDAQ: CYTH) (https://cyclotherapeutics.com)
• CytoSorbents Corporation (NASDAQ: CTSO) (https://CytoSorbents.com)
• Dawson James Securities (https://DawsonJames.com)
• Digital Health Acquisition Corp. (NASDAQ: DHAC) (https://DigitalHealthAcquisition.com) 
• GeoVax Labs, Inc. (NASDAQ: GOVX) (www.GeoVax.com)
• HealthBeacon (OTCQX: HBCN) (https://HealthBeacon.com)
• Heartbeam, Inc. (NASDAQ: BEAT) (www.HeartBeam.com)
• Hillstream BioPharma, Inc. (NASDAQ: HILS) (https://HillstreamBio.com)
• Innovative Eyewear Inc, (NASDAQ: LUCY) (https://Lucyd.co)
• Inuvo Inc. (NYSE American: INUV) (https://Inuvo.com)
• JanOne, Inc. (NASDAQ: JAN) (https://JanOne.com)
• Janover Inc. (NASDAQ: JNVR) (https://JanOver.co)
• Kintara Therapeutics, Inc. (NASDAQ: KTRA) (www.Kintara.com)
• Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) (www.MatinasBiopharma.com)
• NextPlat Corp. (NASDAQ: NXPL) (www.NextPlat.com)
• NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (https://NovaBay.com)
• Neuro Rx Pharmaceuticals (NASDAQ: NRXP) (www.NRXPharma.com)
• Red Cat Holdings, Inc. (NASDAQ: RCAT) (https://RedCat.red)
• SeaStar Medical Holding Corp. (NASDAQ: ICU) (https://SeaStarMedical.com)
• SKYX Platforms Corp. (NASDAQ: SKYX) (https://SkyPlug.com)
• Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) (https://SonomaPharma.com)
• STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (www.StrataSkinSciences.com)
• Windtree Therapeutics, Inc. (NASDAQ: WINT) (https://WindtreeTX.com) 
• Wisa Technologies (NASDAQ: WISA) (www.WisaTechnologies.com)
• ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (www.ZIVOBioscience.com) 
• Zomedica Corp. (NYSE American: ZOM) (https://Zomedica.com)

Platinum Sponsors as of 09/19/2023

• ArentFox Schiff LLP (www.AFSLaw.com)
• Sicheniza Ross Ference Carmel LLP (https://SRF.Law)
• IBN (InvestorBrandNetwork) (www.InvestorBrandNetwork.com)
• IRTH Communications, LLC (www.IRTHCommunications.com)
• SLS Group (www.SLSGroup.io)
• The Money Channel (www.MoneyChannelNYC.com)

Other Sponsors as of 09/19/2023

• Core IR (https://CoreIR.com)
• Greenberg Traurig, PA (https://www.GTLaw.com/en/)
• Jaisin LLC (https://Jaisin.com/Los-Angeles/)
• Skyline Corporate Communications (https://SkylineCCG.com)
• Group, LLC (http://Group-LLC.com)
• The Nuvo Group, Inc (www.TheNuvoGroup.com)
• The Vendor Group (www.TheVendorGroup.com)
• Wall Street Reporting

To learn more, please visit https://ibn.fm/zNaw9

Educators, marketers, social media professionals, thought leaders, and research analysts, are invited to attend the Social Media Strategies Summit Higher Education to be held virtually on October 23-24, 2023, with an optional workshop October 25. The eminent summit aims to reshape the academic landscape with transformative insights, advanced strategies, and unmatched networking opportunities. The summit is committed to revealing the secrets of social media success as it brings together the brightest minds to reveal their unique strategies for growing online communities.

Rewriting the rules of social media promotion and engagement, the Social Media Strategies Summit Higher Education promises to lead the way in higher education transformation. The two-day event will be a game-changer for social media enthusiasts looking to harness the power of digital marketing. With a track record of providing insightful educational experiences, the Social Media Strategies Summit gives people the tools needed to achieve their goals.

Staying at the Forefront of Digital Transformation 

As institutions face the unique challenges of the modern world, the Social Media Strategies Summit Higher Education equips them with the latest insights needed to succeed. The summit will feature panel discussions and interactive sessions where professionals will share proven social media strategies and valuable real-world case studies to drive brand awareness, enrollment, and engagement.

Led by seasoned social media experts, these sessions focus on the art of content planning, data analytics, calendars, creativity, engagement, and more. Attendees will be engrossed with interactive activities, knowledge-sharing, short lectures with small breakout groups, and a chance to ask important questions. It’s a great opportunity for them to connect with solution providers, peers, and professionals in the higher education space. They can explore the latest technologies and share ideas in a learning and collaborative environment. 

Interested participants should enroll for the summit now and be a part of a community that is shaping the future of social media innovation.

Your ticket to the summit also unlocks access to the Corporate Brand Summit on October 26-27.

To learn more, please visit https://ibn.fm/m2yBG.